William R. Davies1, PhD, MRCP, MRCS; Vinayak N. Bapat1, FRCS (CTh); Jane E. Hancock1, MD, PhD; Christopher P. Young1, MD, FRCS (CTh); Simon R. Redwood1,2, MD, FRCP, FACC; Martyn R. Thomas1*, MD, FRCP
1. Cardiovascular Department, St Thomas’ Hospital, London, United Kingdom; 2. BHF Centre of Excellence, King’s College London, Rayne Institute, St Thomas’ Campus, London, United Kingdom
Aims: Transcatheter aortic valve implantation (TAVI) is now the therapy of choice for those patients with severe symptomatic aortic stenosis who are considered to be at too high risk for